Which has preferable valuation and earnings, SVRA or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is SVRA or CELC more profitable?

Savara's return on equity of -90.28% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Celcuity N/A -250.68% -50.23%

Does the media refer more to SVRA or CELC?

In the previous week, Celcuity had 4 more articles in the media than Savara. MarketBeat recorded 22 mentions for Celcuity and 18 mentions for Savara. Celcuity's average media sentiment score of 0.84 beat Savara's score of 0.03 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 8 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Is RLAY or SVRA more profitable?

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Savara N/A -90.28% -68.95%

Does the media favor RLAY or SVRA?

In the previous week, Savara had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 18 mentions for Savara and 13 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.95 beat Savara's score of 0.03 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Savara 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SVRA or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SVRA or ELVN more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Enliven Therapeutics N/A -18.55% -18.09%

Does the media refer more to SVRA or ELVN?

In the previous week, Savara had 12 more articles in the media than Enliven Therapeutics. MarketBeat recorded 18 mentions for Savara and 6 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.81 beat Savara's score of 0.03 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SVRA or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is SVRA or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Parabilis Medicines N/A N/A N/A

Does the media prefer SVRA or PBLS?

In the previous week, Savara had 11 more articles in the media than Parabilis Medicines. MarketBeat recorded 18 mentions for Savara and 7 mentions for Parabilis Medicines. Savara's average media sentiment score of 0.03 beat Parabilis Medicines' score of -0.15 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, TLX or SVRA?

Telix Pharmaceuticals has higher revenue and earnings than Savara. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.00 -$7.12M N/A N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is TLX or SVRA more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Savara N/A -90.28% -68.95%

Does the media prefer TLX or SVRA?

In the previous week, Savara had 10 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 18 mentions for Savara and 8 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.55 beat Savara's score of 0.03 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Savara 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Savara (SVRA) Competitors

$5.38 +0.11 (+2.09%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.38 0.00 (-0.09%)

As of 08/14/2026 07:34 PM Eastern

Compare

SVRA vs. CELC, RLAY, ELVN, PBLS, and TLX

Should you buy Savara stock or one of its competitors? Savara's main competitors and comparable companies include Celcuity (CELC), Relay Therapeutics (RLAY), Enliven Therapeutics (ELVN), Parabilis Medicines (PBLS), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Savara compare to Celcuity?

Savara (NASDAQ:SVRA) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Savara's return on equity of -90.28% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Celcuity	N/A	-250.68%	-50.23%

87.9% of Savara shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Savara has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Celcuity is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Celcuity had 4 more articles in the media than Savara. MarketBeat recorded 22 mentions for Celcuity and 18 mentions for Savara. Celcuity's average media sentiment score of 0.84 beat Savara's score of 0.03 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	8 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Savara presently has a consensus target price of $10.14, suggesting a potential upside of 88.53%. Celcuity has a consensus target price of $153.64, suggesting a potential upside of 67.00%. Given Savara's stronger consensus rating and higher possible upside, equities analysts plainly believe Savara is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Savara beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Savara compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Relay Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Savara has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Relay Therapeutics presently has a consensus target price of $25.83, indicating a potential upside of 30.08%. Savara has a consensus target price of $10.14, indicating a potential upside of 88.53%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Savara	N/A	-90.28%	-68.95%

In the previous week, Savara had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 18 mentions for Savara and 13 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.95 beat Savara's score of 0.03 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Savara has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	283.53	-$276.48M	-$1.57	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

Relay Therapeutics beats Savara on 8 of the 15 factors compared between the two stocks.

How does Savara compare to Enliven Therapeutics?

Savara (NASDAQ:SVRA) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Savara currently has a consensus price target of $10.14, suggesting a potential upside of 88.53%. Enliven Therapeutics has a consensus price target of $72.67, suggesting a potential upside of 23.54%. Given Savara's stronger consensus rating and higher possible upside, equities analysts clearly believe Savara is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Savara had 12 more articles in the media than Enliven Therapeutics. MarketBeat recorded 18 mentions for Savara and 6 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.81 beat Savara's score of 0.03 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

87.9% of Savara shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Enliven Therapeutics' return on equity of -18.55% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Summary

Savara beats Enliven Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Savara compare to Parabilis Medicines?

Savara (NASDAQ:SVRA) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

87.9% of Savara shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, Savara had 11 more articles in the media than Parabilis Medicines. MarketBeat recorded 18 mentions for Savara and 7 mentions for Parabilis Medicines. Savara's average media sentiment score of 0.03 beat Parabilis Medicines' score of -0.15 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Parabilis Medicines' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Parabilis Medicines	N/A	N/A	N/A

Savara presently has a consensus target price of $10.14, indicating a potential upside of 88.53%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.40%. Given Savara's higher possible upside, equities research analysts plainly believe Savara is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Savara beats Parabilis Medicines on 6 of the 9 factors compared between the two stocks.

How does Savara compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Savara had 10 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 18 mentions for Savara and 8 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.55 beat Savara's score of 0.03 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Savara has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Savara.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.00	-$7.12M	N/A	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Telix Pharmaceuticals currently has a consensus target price of $20.40, suggesting a potential upside of 72.59%. Savara has a consensus target price of $10.14, suggesting a potential upside of 88.53%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Telix Pharmaceuticals' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Savara	N/A	-90.28%	-68.95%

Summary

Savara beats Telix Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.08B	$3.72B	$7.05B	$13.10B
Dividend Yield	N/A	3.70%	2.57%	10.45%
P/E Ratio	-9.28	10.67	269.08	25.28
Price / Sales	N/A	1,306.52	604.12	91.83
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	7.69	16.78	12.91	6.24
Net Income	-$118.84M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-7.72%	1.78%	1.10%	1.06%
1 Month Performance	-7.40%	1.16%	1.32%	0.81%
1 Year Performance	76.97%	54.22%	62.43%	20.90%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	2.0437 of 5 stars	$5.38 +2.1%	$10.14 +88.5%	+78.7%	$1.08B	N/A	N/A	20	Trending News Earnings Report Analyst Downgrade Analyst Revision
CELC Celcuity	3.6754 of 5 stars	$90.98 +0.2%	$155.18 +70.6%	+77.3%	$4.46B	N/A	N/A	40	Trending News Earnings Report Analyst Forecast
RLAY Relay Therapeutics	3.3649 of 5 stars	$20.03 +0.5%	$25.58 +27.7%	+485.8%	$4.40B	$15.35M	N/A	330	News Coverage Analyst Forecast
ELVN Enliven Therapeutics	3.145 of 5 stars	$58.14 -2.2%	$72.67 +25.0%	+197.5%	$4.27B	N/A	N/A	50
PBLS Parabilis Medicines	2.0389 of 5 stars	$35.84 +0.3%	$41.67 +16.3%	N/A	$4.23B	N/A	N/A	N/A	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. CELC, RLAY, ELVN, PBLS, and TLX

How does Savara compare to Celcuity?

Summary

How does Savara compare to Relay Therapeutics?

Summary

How does Savara compare to Enliven Therapeutics?

Summary

How does Savara compare to Parabilis Medicines?

Summary

How does Savara compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. CELC, RLAY, ELVN, PBLS, and TLX

How does Savara compare to Celcuity?

Is SVRA or CELC more profitable?

Do institutionals and insiders hold more shares of SVRA or CELC?

Which has more volatility and risk, SVRA or CELC?

Which has preferable valuation and earnings, SVRA or CELC?

Does the media refer more to SVRA or CELC?

Do analysts recommend SVRA or CELC?

Summary

How does Savara compare to Relay Therapeutics?

Which has more volatility & risk, RLAY or SVRA?

Do analysts prefer RLAY or SVRA?

Is RLAY or SVRA more profitable?

Does the media favor RLAY or SVRA?

Do institutionals and insiders have more ownership in RLAY or SVRA?

Which has stronger valuation & earnings, RLAY or SVRA?

Summary

How does Savara compare to Enliven Therapeutics?

Do analysts recommend SVRA or ELVN?

Does the media refer more to SVRA or ELVN?

Which has more risk and volatility, SVRA or ELVN?

Do insiders & institutionals have more ownership in SVRA or ELVN?

Is SVRA or ELVN more profitable?

Which has preferable valuation & earnings, SVRA or ELVN?

Summary

How does Savara compare to Parabilis Medicines?

Do institutionals and insiders believe in SVRA or PBLS?

Which has higher earnings & valuation, SVRA or PBLS?

Does the media prefer SVRA or PBLS?

Is SVRA or PBLS more profitable?

Do analysts recommend SVRA or PBLS?

Summary

How does Savara compare to Telix Pharmaceuticals?

Does the media prefer TLX or SVRA?

Which has more risk & volatility, TLX or SVRA?

Which has better valuation & earnings, TLX or SVRA?

Do institutionals and insiders hold more shares of TLX or SVRA?

Do analysts recommend TLX or SVRA?

Is TLX or SVRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools